Department of Pharmacology, Kagawa University, Japan.
Department of Pharmacology, Kagawa University, Japan.
Kidney Int. 2018 Oct;94(4):650-652. doi: 10.1016/j.kint.2018.05.025.
Aberrant regulation of an alternative pathway of the complement system could be a therapeutic target of C3 glomerulopathy, including dense deposit disease. In the current issue, Békássy and colleagues provide data on enzymatic conversion of C3 by renin in vitro and on the efficacy of a direct renin inhibitor, aliskiren, on systemic and renal complement activation in patients with dense deposit disease.
补体系统替代途径的异常调节可能是 C3 肾小球病（包括致密物沉积病）的治疗靶点。在本期中，Békássy 及其同事提供了关于肾素在体外对 C3 的酶促转化的资料，以及直接肾素抑制剂阿利克仑对致密物沉积病患者全身和肾脏补体激活的疗效数据。
